Study Uncovers Biological Link to Oral Disease in Down Syndrome

Researchers at New York University College of Dentistry have identified a biological mechanism that may help explain why individuals with Down syndrome experience significantly higher rates of periodontal diseases and other oral health complications. The findings, published in Cell Reports, suggest that impaired calcium signaling in the salivary glands leads to reduced saliva production, triggering changes that can negatively affect the oral microbiome and periodontal health.

Approximately 60% to 90% of people with Down syndrome younger than age 35 develop periodontal diseases, far exceeding rates seen in the general population. While oral hygiene and dietary habits may play a role, the new research indicates that underlying biology is also an important contributor.

Using a well-established mouse model of Down syndrome, researchers found that the animals produced significantly less saliva, while their saliva was more acidic and contained elevated levels of inflammatory immune markers. Mouse models are commonly used because they share many genes, physiological processes, and disease pathways with humans. In Down syndrome research, these models carry genetic changes that closely mimic the human condition, allowing scientists to investigate disease mechanisms that cannot be studied directly in people. Although findings in mice require confirmation in human studies, they often provide valuable insight into human biology.

The investigators discovered that store-operated calcium entry, a cellular signaling process essential for saliva secretion, was impaired in the salivary glands. Reduced saliva flow, or hyposalivation, can increase the risk of dental caries and periodontal diseases by limiting saliva’s protective functions, including buffering acids, lubricating oral tissues, and controlling microbial growth.

The study also identified increased inflammation in gingival tissues, impaired mitochondrial function in salivary glands, elevated blood levels of succinate, a metabolite associated with inflammation, and changes in both the oral and gut microbiome. In addition, researchers detected autoantibodies associated with Sjögren syndrome, suggesting individuals with Down syndrome may be at increased risk for the autoimmune condition.

Perhaps most encouraging, treatment with pilocarpine, a medication used to stimulate saliva production in patients with Sjögren syndrome, and following head and neck radiation therapy, significantly increased salivary flow in the mice.

While additional research is needed to determine whether these findings translate into new therapies for people with Down syndrome, the study provides important evidence that biological pathways, not simply oral hygiene behaviors, contribute to this population’s elevated risk of oral disease.